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Abetterunderstandingofthemolecularlinksbetweenobesityanddiseaseispotentiallyofgreatbeneﬁtforsociety.Inthispaperwe
discussproposedmechanismswhereby bariatricsurgeryimprovesmetabolic health,includingacute eﬀectsonglucosemetabolism
andlong-termeﬀectsonmetabolictissues(adiposetissue,skeletalmuscle,andliver)andmitochondrialfunction.Moreshort-term
randomized controlled trials should be performed that include simultaneous measurement of metabolic parameters in diﬀerent
tissues, such as tissue gene expression, protein proﬁle, and lipid content. By directly comparing diﬀerent surgical procedures using
a wider array of metabolic parameters, one may further unravel the mechanisms of aberrant metabolic regulation in obesity and
related disorders.
1.Introduction
Bariatric surgery represents a highly successful treatment
strategy for obesity and secondary diseases such as type
2 diabetes mellitus (T2DM), at least in morbidly obese
patients [1]. Though similar eﬀects may be obtained with
lifestyle intervention [2], many morbidly obese patients
do not succeed in making suﬃcient permanent lifestyle
changes [3]. The success rate of surgery varies depending
on the surgical procedure and individual factors includ-
ing lifestyle/nutrition, age, gender, and genetics/epigenetics
[4, 5]. Besides being an eﬀective treatment for obesity that
decreases mortality and morbidity, bariatric surgery confers
some health risk including renal stone formation and oxalate
nephropathy(calciumoxalatecrystalsinthekidney)[6].Due
to changes to the gastrointestinal tract with malabsorptive
surgery, absorption of vitamins and minerals is aﬀected and
bariatric surgery patients are advised to take micronutrient
supplements [7].
It is of utmost importance to fully understand the
metabolic changes induced by bariatric surgery, as it may
lead to novel treatment strategies for obesity and related
health problems. Because morbidly obese patients undergo-
ing bariatric surgery eﬀectively and consistently lose excess
body weight and reduce obesity-related comorbidity, they
represent a very useful patient group for studying mecha-
nismsthatregulatemetabolichealth.Themostcommonsur-
gical procedures are today performed laparoscopically and
include adjustable gastric band (LAGB), sleeve gastrectomy
(LSG), Roux-en-Y gastric bypass (RYGB), and biliopancre-
atic diversion (BPD). BPD often includes duodenal switch
(BPD/DS) and sleeve gastrectomy. RYGB and BPD show
the best long-term results in terms of fat loss [8, 9]a n d
diabetes resolution [1]. Whereas LAGB and LSG exert their
eﬀects through reduced ventricular volume and food intake,
RYGB and BPD (with sleeve gastrectomy) combine this
eﬀectwithmalabsorptionofnutrientsbymeansofbypassing
a substantial part of the small intestine. In addition, the
intestinal reconﬁguration results in a rapid improvement
of diabetes within days in most patients, which cannot
be entirely ascribed to energy restriction or fat loss [10].
This intriguing observation has led to the hypothesis that2 Journal of Obesity
regulatory factors in the small intestine, including peptide
hormones and nerve signals, are critical in modulating
glucose homeostasis. Thus, the metabolic eﬀects of bariatric
surgery are both dependent and independent of fat loss.
In the present paper, our overall aim was to describe
central mechanisms that may mediate the beneﬁcial eﬀects
of bariatric surgery on metabolic health. Our speciﬁc
objective was ﬁrst to summarize the most important ﬁndings
regarding fat loss-independent eﬀects of bariatric surgery.
Because of the scarcity of data on the acute eﬀects of surgery
on various metabolic parameters, we also discuss longer-
term metabolic eﬀects that may result from a combination
of fat loss and intestinal surgery, including eﬀects on
mitochondria. Finally, our objective was to provide new
perspectives for future research regarding the metabolic
eﬀects of bariatric surgery.
2. AcuteMetabolic Effects of BariatricSurgery
In the weeks following bariatric surgery, patients are limited
to consumption of liquids and their nutrient intake becomes
drastically reduced. Thus, when evaluating the metabolic
eﬀects of bariatric surgery, one must consider the isolated
impact of reduced energy intake versus weight loss. In
healthy lean subjects, energy restriction may induce a
“starvation diabetes” marked by hepatic and peripheral
insulin resistance [11]. In obese individuals, on the other
hand, energy restriction may improve glycemic control and
insulin sensitivity independently of weight loss during the
ﬁrstdays[12].Themetaboliceﬀectsofweightlossmaybegin
to be substantial after 7–10 days of energy restriction [13].
In diabetic obese individuals, four days of energy restriction
improved hepatic insulin sensitivity leading to suppressed
hepatic glucose output and reduced fasting glucose levels
[14].
However, energy restriction cannot fully account for
the acute improvement in glycemic control after intestinal
bypass. Studies comparing intestinal bypass (RYGB) to
energy-restrictive procedures, both of which require patients
to consume only liquids in the ﬁrst weeks postsurgery, show
as p e c i ﬁ ca c u t ee ﬀect on glucose metabolism after RYGB. In
contrast to RYGB [5, 15], the LAGB procedure showed no
ameliorationofdiabetesuntilaconsiderabledegreeofweight
loss had occurred in a randomized controlled trial of obese
diabetic patients [16]. Kashyap et al. showed that only RYGB
and not LSG improved postprandial insulin secretion and
sensitivity despite similar reductions in weight and fasting
insulin levels (subjects were compared 1–3 weeks before
versus 1 week after surgery) [17]. Similarly, a randomized
controlled trial of diabetic patients by Peterli et al. showed
that RYGB but not LSG increased meal-induced insulin
responses 1 week postsurgery, while eﬀects of the diﬀerent
surgical procedures were similar at 3 months, when similar
weight loss was achieved [18]. These observations clearly
point towards mechanisms of acute glucose control that
are unique to intestinal bypass and that are independent of
energy restriction and weight loss.
The acute eﬀects of bariatric surgery on glycemic control
and metabolic health likely involve a combination of several
factors, including insulin secretion, peripheral insulin sen-
sitivity, and hepatic insulin sensitivity. Distinct eﬀects have
been observed with the BPD and RYGB procedures. The
eﬀects of BPD are more due to intestinal reconﬁguration
andmalabsorption,whileRYGBinvolvesagreaterrestriction
of gastric volume (to 30ml versus 300–400ml with BPD).
BPD rapidly improved insulin sensitivity along with a
reduction in insulin secretion and normalization of blood
glucose levels 1 week [19]a sw e l la s1m o n t hp o s t s u r g e r y ,
measured by euglycemic-hyperinsulinemic clamp [20]. On
the other hand, RYGB did not improve peripheral insulin
sensitivity 2 weeks or 1 month postsurgery, also measured
by euglycemic-hyperinsulinemic clamp [21, 22]. Rather,
RYGB may acutely reduce hyperglycemia by increasing food-
induced insulin secretion via increased release of incretins
[18,23],insomecasesresultinginepisodesofhypoglycaemia
[24, 25]. It should be noted that another study of RYGB
patients before versus 6 days after surgery found signiﬁcant
improvement in peripheral insulin sensitivity measured
by intravenous glucose tolerance tests and homeostatic
model assessment (HOMA) [15]. However, euglycemic-
hyperinsulinemic clamp is a superior technique for mea-
suring insulin resistance. It is possible that improvements
in hepatic rather than peripheral insulin sensitivity may
represent a key mechanism of glucose control after RYGB. A
study in mice suggested that restoration of glucose control
after RYGB may be due to reduced endogenous glucose
output via improved hepatic insulin sensitivity, and also
altered intestinal gluconeogenesis [26].
The proposed hypotheses attempting to explain the
surgery-speciﬁceﬀectsonglucosemetabolismremainspecu-
lative. Various mechanisms are likely to contribute [10]. The
lowerintestinal(hindgut)hypothesisproposesthatexclusion
of the proximal intestine leads to a more rapid delivery
of nutrients to the lower intestine, resulting in increased
release of gut hormones that regulate glucose metabolism
(e.g., glucagon-like peptide-1 (GLP-1), peptide Y (PYY),
and oxyntomodulin secreted by L-cells in the distal small
intestine and parts of the colon) [27, 28]. It is possible that
central eﬀects of GLP-1 may contribute to reducing hepatic
insulin resistance and glucose production [29]. Importantly,
a stimulatory eﬀect on the circulating levels of incretins such
as GLP-1 and glucose-dependent insulinotropic polypeptide
(GIP), which augment insulin secretion, was not observed
with energy restriction in diabetic patients [23]. It is
interesting to note that secretion of GIP, which is produced
in K-cells in the proximal intestine, was found to be
increased after RYBG [27] but decreased after BPD [19,
20]. GIP has been shown to promote energy storage in
adipose tissue, and inactivation of GIP in mice was shown
to improve insulin resistance [30]. Moreover, the upper
intestinal (foregut) hypothesis postulates that the proximal
intestinethatisbypassedwithRYGBandBPDreleasesoneor
more factors with adverse eﬀects on glucose metabolism. In
polygenic diabetic rats (Goto-Kakizaki), Rubino et al. found
that duodenal-jejunal bypass enhanced glucose metabolism
independently of food intake and body weight [31]. The
mechanism may involve reduced nutrient contact with the
excluded duodenum [32]. In diabetic humans with a 60cmJournal of Obesity 3
ﬂexibleplasticsleeveinsertedtoinhibitnutrientcontactwith
duodenal mucosa (endoluminal duodenal sleeve), glycemic
control both after and between meals improved consider-
ably already after 1 week without signiﬁcant weight loss
[33].
Neuronal signalling has been implicated as a critical
factor in the postsurgery control of glucose metabolism. The
vagus nerve is a critical regulator of the digestive process as
well as of appetite regulation in the gut-brain-gut axis, and
vagotomy (resection of the vagus nerve) has been used to
treat obesity [34]. More recently, blockage of vagus activity
by an implanted medical device has shown promising eﬀects
on weight loss in humans [35]. Randomized controlled
trials are needed to conﬁrm this eﬀect, and possible acute
eﬀectsonglucosemetabolismwouldbeofparticularinterest.
An acute eﬀect of vagotomy to reduce insulin secretion
was demonstrated several decades ago in rats [36]. Hepatic
glucose production is centrally regulated via the hepatic
branch of the vagus nerve [37]. Thus, vagus nerve function
may at least partially mediate the acute eﬀects of intestinal
bypass surgery on glucose metabolism.
3. Long-Term Effects on InsulinSensitivity,
Glucose Metabolism, andMetabolicTissues
While it is diﬃcult to isolate the fat loss-dependent and
independent eﬀects of bariatric surgery, long-term studies of
bariatric patients indicate that a greater loss of excess body
weight associates with an improved eﬀect on diabetes [1].
When performed in morbidly obese patients, the RYGB and
BPD/DS procedures often reduce body weight to about half
the original weight within the two ﬁrst years, followed by a
stable weight for at least 10 years [8, 9]. Although bariatric
patients usually remain obese after surgery with a body-
mass index (BMI) above 30, their metabolic proﬁle is in
many respects similar to that of healthy, lean individuals.
A prospective study of whole body and muscle insulin
sensitivity before and one year after bariatric surgery found
that weight-stable RYGB patients were more comparable
to lean than weight-matched controls [38]. However, this
beneﬁcial eﬀect of fat loss is not speciﬁc to bariatric surgery,
since shorter-term nutritional intervention and exercise
have also been shown to induce weight loss-independent
improvements in glucose homeostasis [39, 40]. Nonetheless,
bariatric surgery allows for relatively controlled long-term
prospective studies of both moderate and profound fat loss
andhasprovidedimportantinsightintothealteredfunctions
of metabolic tissues in (morbid) obesity.
3.1. Bariatric Surgery and the Functions of Adipose Tissue and
Skeletal Muscle. Adipose tissue performs functions that are
critical to metabolic health, providing a storage buﬀer for
surplus energy and secreting peptide hormones, cytokines,
lipids and other molecules, thereby coordinating metabolic
regulation with other organs [41]. Obesity is characterized
by increased fat mass and altered adipose tissue function,
involving cellular stress responses, changes in extracellular
matrix, inﬁltration of immune cells such as macrophages,
chronicinﬂammation,andpotentialaberrationofadipogen-
esis, angiogenesis, and tissue remodelling. These changes are
related to increased ectopic lipid accumulation and secretion
ofadipokines withpotential adversesystemiceﬀects[42,43].
Bariatric surgery may improve adipose tissue function
via various mechanisms, including an acute reduction in
energy intake, changes in the endocrine and immune-related
functions of the gut, and profound reductions in adipose
tissue mass [44]. There is a paucity of information on the
acuteeﬀectsofbariatricsurgeryonadiposetissuefunctionin
humans. In cultured human subcutaneous adipocytes, GIP
together with insulin was found to activate lipoprotein lipase
[45], suggesting that altered GIP levels after bariatric surgery
may aﬀect lipid uptake in adipose tissue [46].
Several long-term studies of bariatric patients have
revealed important insights into the alterations of adipose
tissue function in obesity. Endoplasmic reticulum stress is
increased in obesity, markers of which were strongly reduced
in both subcutaneous adipose tissue and liver tissue 1 year
after RYGB [47]. Moreover, a reduction in macrophage
inﬁltration and the expression of chemoattractant and pro-
inﬂammatorygeneswasobservedinaglobalgeneexpression
study of subcutaneous adipose tissue before versus 3 months
after RYGB [48]. Our recent microarray study of subcu-
taneous adipose tissue before versus 1 year after BPD/DS
corroborates these ﬁndings, showing a substantial reduction
in genes related to immunity and defense functions [49].
These studies have also demonstrated that bariatric surgery,
most likely due to the profound fat loss, strongly alters the
expressionofgenesinvolvedinextracellularmatrixfunctions
[49, 50]. While similar observations have been made in
dietary intervention studies [51, 52], the diﬀerential gene
expression after bariatric surgery may be speciﬁc to the
extreme degree of fat loss and possibly also some eﬀects of
the gastrointestinal changes after surgery.
Muscle insulin resistance may be a critical factor in
the pathogenesis of diabetes and metabolic complications
including fatty liver [53]. Bariatric surgery was found to
decrease intramyocellular lipids measured by Oil-red-O
staining 3 and 9 months after RYGB or LAGB [54]. The
study also found reduced gene expression of SCD1 and
PDK4 in skeletal muscle after 3 months, whereas PPARα,
MCAD, CPT1,a n dUCP3 were down-regulated only at
the 9-month time point. Greco et al. showed a signiﬁcant
reduction in intramyocellular lipids 6 months after BDP
[55]. A magnetic resonance spectroscopy study also found
signiﬁcant reductions in intramyocellular lipids already 1
monthafterBPD[56],whilethisearlyeﬀectwasnotreported
in a study of seven RYGB patients [57]. Further studies
should be performed to verify whether there is a surgery-
speciﬁc eﬀect on intramyocellular lipids. It is tempting
to speculate whether a reduced circulating level of GIP
speciﬁcally after BPD may play a role, since suppression of
GIP may reduce lipid storage in skeletal muscle and liver as
in adipose tissue [46].
3.2. Bariatric Surgery and Liver Function. The liver is a
critical organ for maintaining metabolic homeostasis in
the body. Lipid homeostasis is typically disrupted in obese4 Journal of Obesity
individuals, reﬂected by chronically elevated plasma lipid
levels. Together with adipose tissue, the liver is the main
lipidemic organ during systemic hyperlipidimia, and the
development of insulin resistance and diabetes [58]. The
liver takes up free fatty acids (FFAs) released from adipose
t i s s u e ,a sw e l la sc i r c u l a t i n gt r i g l y c e r i d e s( T G s ) .T h eF F A s
are either degraded by β-oxidation or repackaged to TGs in
very low-density lipoprotein particles and released into the
bloodstream.
Steatosis (fatty liver) occurs when there is an imbalance
between lipogenesis and fatty acid oxidation. When the
rate of hepatic fatty acid uptake from plasma and de novo
fatty acid synthesis predominates over the rate of fatty
acid oxidation and triglyceride export, triglycerides will be
deposited in the liver. The resulting liver injury is often
associated with obesity, and 95% of individuals with class
III obesity (BMI ≥ 40kg/m2) have alterations in routine
liverbiopsies dueto steatosis, steatohepatitis, orﬁbrosis[59].
These liver abnormalities are known as nonalcoholic fatty
liver disease (NAFLD) which increases the risk of developing
T2DM, dyslipidemia, and hypertension [60]. It is unknown
whether alterations in hepatic glucose, FA, and lipoprotein
metabolism and inﬂammation are causes of NAFLD, or
whether these abnormalities are increased in the presence of
NAFLD. Increased hepatic β-oxidation will generate reactive
oxygen species and promote the development from steato-
sis to the inﬂammatory stage nonalcoholic steatohepatitis
(NASH). Reduced lipid storage eﬃciency in adipose tissue
and increased rates of adipose tissue lipolysis in obesity
promote ectopic lipid accumulation, challenging the liver
with high amounts of FFAs [43].
The amelioration of NAFLD and liver function by
bariatric surgery may be an important contributor to the
systemic improvement of energy homeostasis. Most studies
have shown improved liver histology and liver function as
well as insulin sensitivity in obese subjects with NAFLD
and NASH after bariatric surgery [61] .T h ew e i g h tl o s sa n d
reduced energy overload improve liver parameters, and the
less severe steatosis is fully reversible. In accordance with
this, LAGB changed the hepatic adipokine levels of NAFLD
patients in an anti-inﬂammatory direction, increased the
adiponectin protein level, and decreased the leptin receptor
mRNA level 6 months after surgery [62]. Another study
found that a gene with a central role in lipid peroxidation,
CYP2E1, was signiﬁcantly reduced in liver after weight loss
following bariatric surgery [63]. Hepatic lipid peroxidation,
as measured by the malondialdehyde (MDA) level, was
reduced and liver steatosis decreased from 17% prior to
surgery to 2% several months after. These studies show that
bariatric surgery can improve the more progressed NASH
disease. The amelioration of NAFLD and liver function by
bariatric surgery may be an important contributor to the
systemic improvement of energy homeostasis. However, the
lack of randomized clinical trials so far makes it diﬃcult to
conclude on the use of bariatric surgery for treatment of
NASH [64].
Intriguingly, no reduction in intrahepatocellular lipid
levels was observed 1 month after RYGB while insulin
sensitivity markedly improved [57]. This was surprising
given the strong link between hepatic lipid levels and insulin
resistance. On the other hand, hepatic lipid content was
markedly reduced by 6 and 12 months. Of note, neither
visceral adipose tissue mass nor intramyocellular lipid levels
correlated with the improvements in insulin sensitivity.
These observations should be validated in short-term ran-
domized studies with increased power and in subjects
undergoing diﬀerent forms of bariatric surgery. This may
provideimportantnewinsightintothemechanismswhereby
bariatric surgery aﬀects the systemic metabolic homeostasis
via the individual metabolic tissues. Development of insulin
resistance in the liver may also partly result from the altered
secretion of metabolic and inﬂammatory adipokines from
adipose tissue [58, 65]. The general metabolic eﬀects of
bariatric surgery are summarized in Figure 1.
4. MitochondriainObesityand
DiabetesMellitus
4.1. Mitochondria before Bariatric Surgery. Mitochondrial
metabolism is essential in maintaining normal physiological
function in human cells, for example, by providing energy in
the form of ATP and performing fatty acid (FA) oxidation.
These metabolic functions are reduced in insulin-responsive
tissues (muscle and adipose tissue) in obesity and T2DM.
No consensus has been reached so far whether insulin
resistance is a result of reduced mitochondrial density and
whether it is the cause or consequence of mitochondrial
dysfunction [66–76]. In general, insulin regulates protein
synthesis, glycolysis, and glucose storage in muscle and
liver, lipid synthesis, and storage in liver and adipose tissue,
and inhibits gluconeogenesis and ketogenesis in liver [77].
In particular, insulin signalling was shown to inﬂuence
mitochondrial DNA and protein synthesis and aﬀect mito-
chondrial respiration and ATP production [78]. Factors
that may cause mitochondrial dysfunction include genetic
defects, age, physical inactivity, and nutritional overload.
These factors may exert changes in mitochondrial size and
content, activity and coupling of mitochondrial respiration,
copy numbers of the mitochondrial genome, reactive oxygen
species (ROS) production, FA oxidation, and more.
Altered gene expression and protein levels may reﬂect
the status of mitochondrial function in obesity and related
diseases. Reduced expression of speciﬁc genes in myocytes
was proposed to result in mitochondrial dysfunction in
patients with T2DM. For example, the expression of several
genes encoding enzymes involved in the electron transport
chain was reduced in muscle of family history-positive
nondiabetic subjects and subjects with T2DM [79, 80].
However, this reduced mRNA expression was not reﬂected
in a reduced respiratory rate per mitochondrion in insulin-
resistant muscle [66]. The expression of several genes of the
FA oxidation pathway was also decreased in skeletal muscle
inT2DM[80].Moreover,genesrelatedtomitochondrialbio-
genesis, such as peroxisome proliferator-activated receptor γ
coactivator-1 (PGC-1α and PGC-1β), were similarly down-
regulated in diabetes [79, 80]. Another study attributed
the decreased skeletal muscle FA oxidation in obesity toJournal of Obesity 5
Bariatric surgery
Skeletal muscle
Liver Adipose tissue
Weight loss independent (RYGB, BPD)
Weight loss dependent (AGB, LSG, RYGB, BPD)
↑ Insulin sensitivity
Glucose tolerance
↓ Hyperlipidemia
↑ Insulin sensitivity
Glucose tolerance
↓ Hyperlipidemia
↑ Insulin sensitivity
Glucose tolerance
↓ Hyperlipidemia
Morbidity and mortality ↓
Figure 1: Scheme of the metabolic changes in response to adjustable gastric band (AGB) and laparoscopic sleeve gastrectomy (LSG), whose
metabolic eﬀects are mainly dependent on weight loss, and Roux-en-Y gastric bypass (RYGB) and biliopancreatic diversion (BPD), whose
metabolic eﬀects are also independent of weight loss.
reduced mitochondrial content (and not to intrinsic mito-
chondrial defects), but showed no reduction in the protein
levelsofPGC-1α,PGC-1β,peroxisomeproliferator-activated
receptor α (PPARα), or the mitochondrial transcription
factor A (TFAM). Instead, the protein level of PPARγ was
increased, possibly due to decreased FA oxidation [81].
Furthermore,ithasbeenproposedthatmitochondrialfusion
and metabolism in obese and non-obese T2DM patients is
impaired due to reduced expression of mitofusin 2 (MFN2)
in skeletal muscle [82–84]. MFN2 is an outer mitochondrial-
and endoplasmic reticulum membrane protein with fusion
activity important for mitochondrial dynamics and mor-
phology [83–85]. MFN2 transcriptional activation is reg-
ulated by both PGC-1α and β and the estrogen-related
receptor α (ERRα). More studies are needed to delineate the
molecularmechanismsresponsibleforalteredmitochondrial
function in obesity.
It is of potential interest to compare diﬀerent adipose
tissue depots regarding mitochondrial function. Increased
visceral (intra-abdominal) adipose tissue mass is particularly
associated with risk of metabolic disease relative to subcu-
taneous fat. Diabetic humans show decreased expression of
respiratory rate genes in visceral adipose tissue compared
to healthy humans [87]. It has also been shown that
visceral adipose tissue contains twice as many, but smaller,
mitochondria per milligram of tissue than the subcutaneous
depot [87]. This resulted in visceral fat eliciting lower
mitochondrial respiration than subcutaneous fat, when
expressed per cell. However, per milligram tissue visceral fat
was metabolically more active than subcutaneous fat.
4.2. Mitochondrial Regulatory Pathways and Biogenesis after
Bariatric Surgery. Mitochondrial function is destabilized
in obesity and T2DM, but few studies have speciﬁcally
investigated the eﬀect of bariatric surgery on mitochondrial
metabolism in myocytes and adipocytes. Bariatric surgery
has been shown to induce severalfold changes in the expres-
sion of genes encoding proteins involved in mitochondrial
function and biogenesis in muscle and adipose tissue. In
a global gene expression study of subcutaneous adipose
tissue before versus 1 year after BPD/DS [49], we observed
an altered expression of certain genes involved in the
mitochondrial electron transport chain. These alterations
included an up-regulation after surgery of ATP5G2,w h i c h
encodes a subunit of the mitochondrial ATP synthase,
and of COX5B, the nuclear-encoded Vb subunit of the
cytochrome c oxidase (COX) complex. The multi-subunit
COX complex transfers electrons from cytochrome c (CYCS)6 Journal of Obesity
Normal glucose tolerance T2DM
↑ Insulin sensitivity ↓ Insulin sensitivity
SAT mitochondria SAT mitochondria
Skeletal muscle
mitochondria
Skeletal muscle
mitochondria
↓ MFN2
↓ ATP5G2
↓ COX5B
↑ CYCS
↑ SLC25A25/37/44
↑ PGC-1α, PGC-1β,
PPARδ, SIRT1
↑ MFN2
↑ VDAC1
↑ CS
?
Figure 2: Summary of altered mitochondrial and mitochondrial biogenesis (boxed) gene expression in skeletal muscle of morbidly obese
patients with normal glucose tolerance or type 2 diabetes mellitus (T2DM) [86] and in subcutaneous adipose tissue (SAT) one year after
BPD/DS surgery [49]. Arrows indicate the direction of the altered gene expression after bariatric surgery.
to molecular oxygen to form water. The expression of
CYCS, on the other hand, which is also an intermediate
in apoptosis, was down-regulated in adipose tissue after
bariatric surgery. In addition, three genes of the solute
carrier family (SLC25A25, SLC25A37, SLC25A44), involved
in shuttling phosphate, iron, and adenine nucleotides
across the inner mitochondrial membrane, were signiﬁ-
cantly down-regulated postsurgery. Another study investi-
gated alterations in skeletal muscle mitochondrial function
two years after BPD surgery, comparing morbidly obese
patients to patients with normal glucose tolerance (NGT)
and T2DM [86]. It was demonstrated that BPD surgery
increased insulin sensitivity in both NGT and T2DM
patients, an eﬀect that did not correlate with induced
mitochondrial gene expression in the diabetic patients
(Figure 2). NGT patients showed an increased expression
of genes regulating mitochondrial biogenesis in skeletal
muscle, including PGC-1α, PGC-1β, PPARδ,a n dSIRT1 (a
gene that regulates PGC-1α expression in liver and muscle)
[86]. The expression of other mitochondrial genes such
as MFN2 and the constitutive genes porin (VDAC1)a n d
citrate synthase (CS) were also signiﬁcantly increased in
the NGT patients. In the diabetic patients, no change was
observed with the exception of MFN2 which was down-
regulated. Moreover, a diﬀerential oxidative proﬁle in line
with the mitochondrial gene expression could be observed
in the two groups. Glucose oxidation during fasting was
higher in the NGT group and lipid oxidation was higher
in the diabetic group after BPD surgery. These results
suggest a diﬀerential regulation of mitochondrial function
in response to BPD in patients with NGT and T2DM,
respectively.
5.FuturePerspectives
Many aspects of the metabolic eﬀects of bariatric surgery
remain inadequately addressed or unanswered. There is
convincingevidencethatbariatricsurgeryexertsacuteeﬀects
on metabolism that are independent of energy restriction
and fat loss. The role of incretins on the metabolic functions
of the liver, adipose tissue, and skeletal muscle should be fur-
ther investigated. Molecular biology tools including global
gene expression analysis and proteomics should be applied
on tissue biopsies and isolated cell fractions collected before
and shortly after bariatric surgery. Since certain biopsies are
diﬃcult to obtain from humans (e.g., postoperative visceral
fat), the rat may be a useful model for studying the acute
as well as long-term metabolic eﬀects of bariatric surgery
in all tissues [88–90]. In humans, short-term randomized
controlledtrialswithincreasedpoweranddirectcomparison
of diﬀerent surgical procedures should be performed, and
these would be strengthened by simultaneous measurement
of tissue-speciﬁc metabolic parameters. More detailed analy-
sis of parameters such as mitochondrial function may reveal
novel mechanisms that may be targeted for more successful
treatment of obesity and related diseases. The acute and
long-term eﬀects of speciﬁc bariatric surgery procedures
on tissue and mitochondrial functions should be further
investigated.
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